Navigation Links
Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
Date:4/28/2009

RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the Bank of America and Merrill Lynch 2009 Health Care Conference in New York City on Tuesday, May 12, 2009 at 12:40 p.m., Eastern Time.

An audio webcast of the presentation will be available at www.transcept.com. The audio replay of the presentation will be available at the same location through May 26, 2009.

About Transcept Pharmaceuticals (TSPT)

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved as anticipated, Intermezzo(R) will be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA), which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at:

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences ... cooperative research and development agreement (CRADA) with Aratana ... the development of TRB-N0224 for the treatment and ... dogs and cats.  Traverse Biosciences has also granted ... the treatment and control of periodontal disease in ...
(Date:5/4/2015)... - The Fight Against Cancer Innovation Trust (FACIT) ... formation of Turnstone Biologics Inc. (Turnstone), a biotechnology ... harness the patient,s own immune system. ... Children,s Hospital of Eastern Ontario ... Institute for Cancer Research (OICR), the Ottawa Hospital ...
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... , , , COVINA, Calif., Aug. ... today announced that Shannon Miller , a 7-time Olympic Medalist and ... in a series of advertising and public awareness campaigns for the company. ... , Considered "The Most Decorated American Gymnast" by ...
... , , ROCKVILLE, ... the release of 5,000 purified human proteins, representing the ... , OriGene,s recombinant proteins are purified ... Mammalian cell expressed proteins are superior to other ...
... , NEW YORK, Aug. 24 NeoStem, Inc. (Amex: ... long-term storage of adult stem cells for future medical need, announced today ... York Department of Taxation and Finance, for the period ending December 31, ... shareholders that, as a result of this designation, they may be eligible ...
Cached Biology Technology:7-Time Olympic Medalist Shannon Miller Endorses StemCyte 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 3
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2
... abundant biomass material on Earth, and therefore represents an ... production of advance biofuels. A major roadblock, however, has ... the U.S. Department of Energy (DOE),s Joint BioEnergy Institute ... roadblock by identifying a gene in rice plants whose ...
... toxic pesticides" and "pesticides as a last resort" have ... scientific organizations the Weed Science Society of America ... Ecosystems Section of the Entomological Society of America (P-IE ... the pesticide component of an Integrated Pest Management (IPM) ...
... American Societies for Experimental Biology (FASEB) is rallying the ... facing the nation,s research agencies unless Congress acts before ... Institutes of Health (NIH) could lose $2.8 billion and ... Science Foundation (NSF) could be cut by nearly $600 ...
Cached Biology News:A better route to xylan 2A better route to xylan 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 2Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 4Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 5FASEB urges biomedical research community to speak out against sequestration 2
... The RapidPlate 96/384 workstation offers precise 96 ... scalable format. Utilizing 100ul and 200ul disposable ... delivers excellent accuracy and precision across a ... rotary deck includes two positions that enable ...
... Rabbit Tissue Arrays contain 60 rabbit tissue samples ... contains 4 unstained slides and 1 hematoxylin and ... slide contains 15 different tissues from 4 rabbit ... per slide. Each tissue sample (or core) is ...
A univariate (peak height or area) quantitative multi-component analysis package....
... micro 10 represents a major advance in ... the benefits of large robotic liquid handlers ... dispenser. Dispensing accurate volumes ranging from 10mL ... has unique advantages not yet found in ...
Biology Products: